Entheon Biomedical Corp.: Entheon Biomedical Lists on OTCQB Venture Market
Entheon or the
Company ), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has been approved for trading on the OTCQB Venture Market ( OTCQB ) effective May 5, 2021. We are thrilled to be up-listing on to the OTCQB, which will allow for greater engagement with our U.S. investor base. As we advance our DMT addiction therapy program toward human trials, continue R&D on our diagnostic and patient-monitoring platform, and scale up commercial availability of our subsidiary, HaluGen Life Science s Psychedelics Genetic Test, we are pleased to be gaining increased visibility and investor access within the U.S. market, said Timothy Ko, CEO of Entheon.
Entheon Biomedical Lists on OTCQB Venture Market
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Can A Genetic Test Prevent Risk In Psychedelic Therapy? These Companies Are Betting On It
forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
The candidates are:
MYCO – 001: a form of pure psilocybin derived from natural fungal sources, targeted to be used at mid-to-late-stage clinical trials.
MYCO – 002: an empathogen with similar effects to MDMA that could have an improved safety profile.
MYCO – 003: a psilocybin-based formula that could diminish the possibility of bad experiences by reducing patient anxiety.
MYCO – 004: a hallucinogen delivered transdermally, offering precision dosing and long-term compound stability.
The claims presented for these compounds need to be proven in clinical trials and via further research.
“By increasing the complexity of these compounds, we are increasing layers of patents applied, which in turn, also adds pharmaceutical value to the drug candidates,” said Joshua Bartch, co-founder and CEO of Mydecine.